Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1510079
This article is part of the Research Topic Advancements in Multi-Omics and Bioinformatics for the Management of Solid Malignancies View all 14 articles

Integrating Necroptosis into Pan-Cancer Immunotherapy: A New Era of Personalized Treatment Author and affiliations

Provisionally accepted
Yan Gao Yan Gao 1*Sheng Chen Sheng Chen 2*Lei Li Lei Li 3*
  • 1 Department of Respiratory and Critical Care Medicine, The Affiliated Huai’an Hospital of Xuzhou Medical University, Huai'an, China
  • 2 Department of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Naning Medical University, Huai'an, China
  • 3 The Affiliated Huaian No.1 People’s Hospital of Naning Medical University,, sujiang, China

The final, formatted version of the article will be published soon.

    This study investigates necroptosis as a promising biomarker for predicting immunotherapy responses across various cancer types. Through a comprehensive pan-cancer analysis using bulk RNA sequencing data, we developed a necroptosis-related gene signature, Necroptosis.Sig, designed to predict responses to immune checkpoint inhibitors (ICIs). Our multi-omics approach highlighted critical pathways and regulators of necroptosis, with HMGB1 emerging as a key modulator that may enhance immune activation and therapeutic outcomes. Functional validation in A549 lung cancer cells showed that HMGB1 knockdown significantly suppressed tumor proliferation and malignancy, reinforcing necroptosis’s potential as a therapeutic target. These findings underscore the utility of necroptosis as a biomarker to guide personalized immunotherapy strategies, advancing precision oncology in cancer treatment.

    Keywords: necroptosis, machine learning, Pan-cancer analysis, immune microenvironment, Immunotherapy

    Received: 12 Oct 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Gao, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yan Gao, Department of Respiratory and Critical Care Medicine, The Affiliated Huai’an Hospital of Xuzhou Medical University, Huai'an, China
    Sheng Chen, Department of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Naning Medical University, Huai'an, China
    Lei Li, The Affiliated Huaian No.1 People’s Hospital of Naning Medical University,, sujiang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.